Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694177 | 0.90 | KMT2A (0.40) | ALDH1A1TDP1USP2ALOX15GSK3A | |
| SCHEMBL4102344 | 0.76 | CYP11B1 (0.39) | TDP1GSK3AGSK3BKMT2ACYP1A2 | |
| SCHEMBL11433889 | 0.75 | MIF (0.38) | ALDH1A1KMT2AGAASMN1; SMN2NFKB1 | |
| SCHEMBL19552512 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TDP1USP2ALOX15KMT2A | |
| SCHEMBL5213144 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TDP1USP2ALOX15KMT2A | |
| SCHEMBL11214773 | 0.74 | — | — | |
| SCHEMBL13039643 | 0.72 | F2 (0.40) | — | |
| SCHEMBL3491651 | 0.71 | NPC1 (0.39) | CYP1A2NFKB1NFKB2RELARAB9A | |
| SCHEMBL10315910 | 0.70 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15GSK3A | |
| SCHEMBL1254599 | 0.69 | CYP2D6 (0.49) | ALDH1A1KMT2ACYP1A2POLBHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2024-08-06 | — | — | US | disclosed |
| CN-109415387-B | Arginase inhibitors and therapeutic uses thereof | 昂科艾伦迪治疗法公司 | 2021-08-27 | — | — | CN | disclosed |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| EP-3452485-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2020-09-09 | — | — | EP | disclosed |
| EP-3452485-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2020-09-09 | — | — | EP | disclosed |
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2019-08-27 | — | — | US | disclosed |
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2019-08-27 | — | — | US | disclosed |
| EP-3452485-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Oncoarendi Therapeutics SA (PL) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191130-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
| US-5137035-A | With combustible filler of natural tobacco, reconstituted tobacco or tobacco substitutes | PHILIP MORRIS INCORPORATED (US) | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | ALDH1A1 675/4885TDP1 829/4885USP2 1088/4885 |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | ARG1, ARG2, ARGLU1 | ALDH1A1 675/4885TDP1 829/4885USP2 1088/4885 |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | ALDH1A1 675/4885TDP1 829/4885USP2 1088/4885 |
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | ALDH1A1 675/4885TDP1 829/4885USP2 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.